Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00053599 · ClinicalTrials.gov registry record · Phase 3

Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study

A Phase 3 study, sponsored by National Institute on Aging (NIA).

Completed
Registry status
Phase 3
Development phase
400
Enrollment target

NCT00053599: Completed Phase 3 study, sponsored by National Institute on Aging (NIA).

NCT00053599 is a Phase 3 study that has completed, run by National Institute on Aging (NIA). The registered enrollment target is 400 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00053599, a Phase 3 study, has completed, sponsored by National Institute on Aging (NIA).

COMPLETED
Registry status
Phase 3
Development phase
400 participants
Enrollment target

Study Summary

CLASP is a research study to investigate the safety and effectiveness of simvastatin (a cholesterol lowering drug or statin) to slow the progression of Alzheimer's disease (AD). Statins are commonly used to treat high cholesterol levels, which increase the risk of heart disease and stroke.

Interventions

  • DRUG Simvastatin

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2002-12
Est. Completion 2007-10
Phase Phase 3
National Institute on Aging (NIA)

131 total trials

What the finished NCT00053599 record still lists

NCT00053599 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower).

The record links to 0 conditions, and to 1 intervention - of which Simvastatin is the first listed.

NCT00053599 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00053599 about?

NCT00053599 is a clinical study titled "Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study". CLASP is a research study to investigate the safety and effectiveness of simvastatin (a cholesterol lowering drug or statin) to slow the progression of Alzheimer's disease (AD). Statins are commonly used to treat high cholesterol levels, which increase the risk of heart disease and stroke.

What is the current status of trial NCT00053599?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2002-12. Estimated completion is 2007-10.

What interventions are being tested in trial NCT00053599?

The interventions under investigation include: Simvastatin (DRUG).

Who is sponsoring clinical trial NCT00053599?

This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00053599's enrollment target sits among peer trials

400 922nd of 2000 higher than 1,039 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01665326 · 400 participants

    Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

  • NCT02108054 · 400 participants · NA

    Behavioral and Functional Task Development, Implementation, and Testing

  • NCT02216500 · 400 participants · NA

    Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy

  • NCT02250352 · 400 participants

    Core Biopsies for Establishing a Breast Tumor Tissue Repository

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00053599, the US trial registry maintained by the National Library of Medicine. NCT00053599 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.